Market research

RVLPQ RVL Pharmaceuticals plc

NASDAQ USD Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market cap: 1K
P/E ratio: Not available
Analyst target: Not available
Dividend yield: Not available
Beta: 43.19

Loading price history…

Profile

Company facts

Exchange: NASDAQ
Currency: USD
Sector: Healthcare
Industry: Biotechnology
ISIN: IE00BF2HDL56
Market cap: 1K
P/E ratio: Not available
Analyst target: Not available
Dividend yield: Not available
Beta: 43.19

About

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, Argentina, and Hungary. It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Visit company website

Reported results

Fundamentals

Open this section to load reported financial history.

Annual returns

No comments yet

Start a focused discussion about RVLPQ.

RVLPQ RVL Pharmaceuticals plc

Price & volume

Company facts

About RVL Pharmaceuticals plc

Fundamentals

Earnings

Cash flow

Profitability

Valuation

Performance

Annual returns

Investor discussion

No comments yet